

# Cell Engager Summit



---

## ABOUT › AGENDA

---

ACCOMMODATION



ABOUT EVENT



FULL EVENT GUIDE



SPEAKERS



PRE-CONFERENCE WORKSHOPS



AGENDA



VENUE



MEDIA HUB



Download the  
Brochure



## Day One

Tuesday - March 31, 2020

## Day Two

Wednesday - April 1, 2020

8:00 am Registration & Networking Coffee

8:50 am Chair's Opening Remarks

*Divya Mathur*

Associate Research Fellow, Pfizer

Assessing Current Limitations of Cell Engagers including Strategies to Mitigate Toxicities to Ensure Patient Safety

9:00 am XTENylated Protease Activated T Cell Engagers: XPATS – A Novel Format to Mitigate the On-target, Off-tumor Problem

*Volker Schellenberger*  
President & CTO , Amunix

**9:30 am** T Cell Engaging Antibody Circuits (TEAC): Focusing Immune Activation to the Cancer Cell Surface to Widen the Therapeutic Index

*Patricia Giblin*  
VP of Biology, Revitope

**10:00 am** TriTACs Are T Cell Engaging Drugs for Treatment of Solid Tumors

*Rick Austin*  
Senior Director of Biology Research, Harpoon

**10:30 am** Speed Networking & Morning Refreshments

**12:00 pm** Panel Discussion: Exploiting the High Protease Concentration in the Tumor Microenvironment to Reduce Toxicity

*Holger Wesche*  
CSO, Harpoon Therapeutics Inc.

*Volker Schellenberger*  
President & CTO , Amunix

*Chad May*  
Senior Vice President - Research & Development, Maverick Therapeutics

**12:45 pm** Networking Lunch

**Improving the Therapeutic Window of Cell Engagers: Addressing Half-Life and Cytokine Release Syndrome**

**2:00 pm** Discovering and Designing the Next Generation of T cell Engagers

*Omid Vafa*

CBO, TeneoBio

### 2:30 pm Optimizing Therapeutic Index and Other Properties with Potency Reduction and Bivalent Target Engagement

*John Desjarlais*

CSO, Xencor

### 3:00 pm CB307: A Novel T cell Enhancing Humabody Bispecific

*James Legg*

SVP of Research, Crescendo Biologics

3:00 pm

*Johan Kers*

VP Research, AbSci

#### Synopsis

- T Cell Engagers with poor manufacturability can be improved using engineered *coli* SoluPro<sup>®</sup> cell lines
- Cell Engagers with poor manufacturability can be improved using engineered *coli* SoluPro<sup>®</sup> cell lines
- A novel synthetic biology strategy using *coli* SoluPro<sup>®</sup> enables rapid and soluble expression of T Cell Engager proteins
- Precise engineering of protein expression conditions, folding solutions, and cytoplasmic conditions enable optimization of parameters for production of high titer, high quality therapeutics

3:30 pm Afternoon Refreshments & Networking

#### Review of Current Clinical Data

### 4:00 pm Translating Preclinical BiTE<sup>®</sup> Data to the Clinic

*Julie Bailis*

Principal Scientist, Amgen

### 4:30 pm Flotetuzumab: An Experimental CD123 x CD3 Bispecific DART Molecule for the Treatment of AML

*Jan Davidson*

Director of Clinical Development & Research , Macrogenics

### 5:00 pm AMV564 Relieves Immune Suppression Through Selective Targeting of CD33

*Victoria Smith*

CSO, Amphivena

### 5:30 pm Chair's Closing Remarks & End of Day One

[NEXT PAGE: PRE-CONFERENCE WORKSHOPS](#)

[CLICK HERE >](#)



---

#### OUR CONTACT DETAILS

T: (+1) 617 455 4188

E: [info@hansonwade.com](mailto:info@hansonwade.com)

---

#### VENUE DETAILS

Boston, MA

---

#### ABOUT US

Hanson Wade's goal is to accelerate progress within organisations and across industries. Our primary method for achieving this is by creating exclusive business conferences that gather together the world's smartest thinkers and doers.

---

#### LOCATION

[Grotere kaart weergeven](#)



[Kaartgegevens](#) [Gebruiksvoorwaarden](#)

## SEARCH

## ORGANISED BY



# hansonwade

[Terms & Conditions](#)

[Privacy Policy](#)

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.

Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.